GET DAILY SIGNALSAlcon Inc. (ALC): Analyst Targets Suggest Potential +14% Move to $86
Key Takeaways
- The central target used here is $86, calculated as the average of verified analyst price targets that sit above the latest market price of $75.14.
- That $86 figure is roughly 14% above the current price, requiring a substantial but not extreme advance.
- The overall mean of all recent analyst targets reviewed is about $82, with individual targets ranging from approximately $70 to $98.
- Bullish cases rest on premium intraocular lenses (IOLs), contact-lens momentum, and the Neurotech acquisition; bearish cases cite valuation and competitive pressure.
- The $86 target sits essentially at the stock's 52-week high near $87.64, making that level a key technical hurdle.
- For more detail on this ticker, explore the Major News, Today's Price Move, Forecast, and Earnings pages.
- To see how AI-driven trading systems are positioned across the market, explore Trending AI Robots.
Analyst Price Targets and Consensus View
Alcon Inc. (ALC), the global eye care company operating through its Surgical and Vision Care segments, is covered by roughly two dozen sell-side analysts. Reviewing ten recent, attributable targets, the range runs from about $70 to $98. The most bullish is Needham's David Saxon, who reiterated a Buy with a $98 target in early November 2026. The low end is set by Barclays (initiating coverage with an Equal-Weight and a $70 target in October) and Stifel, which holds a $70 target.
Calculating the arithmetic mean of all ten targets produces an overall average near $82, only about 9% above the $75.14 market price — below the 10% threshold used for this exercise. Because several targets (BTIG at $74, Barclays at $70, Stifel at $70) now sit below the market price, the central target here is the average of the seven targets that remain above the current price. That average is $86, rounded from $85.91. This is a calculated figure, not an officially published consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Views are split. KeyBanc trimmed its target to $84 from $88 in late October, Mizuho to $80 from $85, and Jefferies to $85 from $95 in September, while Wells Fargo holds an Overweight rating with an $86 target and Baird a $90 target. Bank of America remains a notable bear with an Underperform stance. The repeated downward target revisions in recent months reflect softer market conditions and competitive pressure even as ratings have largely stayed positive.
Current Market Position and Path Toward the Target
At its most recent close of $75.14, Alcon Inc. (ALC) trades well off its 52-week high of $87.64 set in February 2026 and above its 52-week low of $61.84 from May 2026. Reaching $86 would require an advance of roughly 14%, a substantial move that would return the stock to essentially its prior peak.
The path toward that level depends on execution across both divisions. Alcon reported better-than-expected second-quarter 2026 results in August, beating on earnings per share (EPS) and raising its outlook, which briefly lifted shares. Forward estimates point to fiscal 2026 EPS near $3.49 on revenue approaching $11 billion. With a trailing price-to-earnings (P/E) ratio above 50, however, the stock already embeds meaningful expectations, meaning progress would likely have to be driven by continued earnings delivery rather than multiple expansion alone.
What Could Support a Move Toward the Target
- Premium IOL growth: Alcon's advanced-technology intraocular lenses, including the UNITY portfolio, command higher margins and support the razor-and-blade surgical franchise.
- Vision Care momentum: Contact lenses and ocular health products provide recurring revenue and have been a stable growth driver.
- Neurotech acquisition: The $550 million purchase adds the FDA-approved ENCELTO retinal therapy, extending Alcon into cell and gene therapy for retinal disease.
- Guidance and revisions: Post-earnings target raises from Needham and Mizuho in August, and Wells Fargo's February upgrade, show pockets of analyst confidence.
- Aging demographics: Structural demand from an aging global population supports long-term eye care volumes.
What Could Prevent the Target From Being Reached
- Elevated valuation: A trailing P/E above 50 leaves little room for disappointment if growth slows.
- Competitive pressure: Rivals in contact lenses and IOLs have kept pricing and share gains contested.
- Downward target drift: Multiple firms have trimmed targets since September, a sign of moderating near-term expectations.
- Currency and macro factors: As a Swiss-headquartered company, foreign exchange swings and broader healthcare spending trends can weigh on results.
- Elevated short interest: A rising short position indicates a segment of the market is positioned against further gains.
Technical Levels and Market Structure
The most important chart level is the 52-week high near $87.64, which sits almost directly at the $86 central target and represents a clear resistance zone from the stock's February 2026 peak. A decisive move above that area would be a notable structural shift. On the downside, the 52-week low of $61.84 and the mid-$60s zone that held in September and October mark major support. The stock's recovery from its spring low through the low-to-mid $70s leaves it in a broad recovery channel, but it has not yet retested its prior highs.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms vary and Alcon's targets have been revised frequently in 2026. Investors should monitor the company's third-quarter 2026 results, which are due imminently, along with any changes to full-year guidance. Additional signals include updates on the UNITY IOL and other premium lenses, integration progress on the Neurotech portfolio, foreign exchange trends, and any further analyst revisions. Given the target sits at the 52-week high, a breakout or rejection at that level will be a key tell for the stock's market outlook. From what I see, monitoring these elements closely helps clarify the setup.
Final Assessment
Can Alcon Inc. (ALC) stock reach $86? The figure represents the average of analyst price targets that remain above the current $75.14 price, and it implies a substantial gain of roughly 14%. Support comes from premium IOL growth, a resilient Vision Care franchise, and a strategic step into retinal cell therapy, while the principal obstacles are a demanding valuation, competitive pressure, and a pattern of downward target revisions. The overall analyst mean of about $82, with a range of roughly $70 to $98, underscores genuine disagreement about how much upside remains. With the target essentially matching the stock's 52-week high near $87.64, the coming earnings report and whether shares can reclaim that level will be the clearest signals of whether a move toward $86 is realistic. No outcome is guaranteed.
Exploring Tickeron AI Tools for Deeper Insights
In my analysis of names like Alcon Inc. (ALC), I often turn to Tickeron’s AI Daily Buy/Sell Signals to track momentum shifts alongside traditional research. The platform applies artificial intelligence to scan thousands of stocks and ETFs, delivering Buy, Sell, or Hold signals based on technical patterns and market changes. It serves as a practical complement for monitoring positions without replacing core due diligence, helping highlight when trends may be accelerating or reversing.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for ALC turns positive, indicating new upward trend
ALC saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 61 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ALC just turned positive on October 09, 2026. Looking at past instances where ALC's MACD turned positive, the stock continued to rise in 32 of 53 cases over the following month. The odds of a continued upward trend are 60%.
ALC moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ALC crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 60%.
Following a +3.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALC advanced for three days, in 175 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
The Aroon Indicator entered an Uptrend today. In 95 of 218 cases where ALC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 44%.
Bearish Trend Analysis
The 10-day RSI Indicator for ALC moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 17 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 61%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 67 cases where ALC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
ALC broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. ALC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.678) is normal, around the industry mean (4.964). P/E Ratio (56.773) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (1.165) is also within normal values, averaging (4.143). Dividend Yield (0.014) settles around the average of (0.005) among similar stocks. P/S Ratio (2.996) is also within normal values, averaging (56.876).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer and manufacturer of surgical & eye care device
Industry PharmaceuticalsOther
Advertisement